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Abstract 
Colorectal cancer (CRC) screening has been shown to reduce CRC incidence and mortality and 
is widely recommended. However, despite the demonstrated benefits of screening and ongoing 
efforts to improve screening rates, a large percentage of the population remains unscreened. 
Noninvasive stool based tests offer great opportunity to enhance screening uptake. The evidence 
supporting the use of both fecal immunochemical testing (FIT) and stool DNA (sDNA) has been 
growing rapidly and both tests are now commercially available for use. Other stool biomarkers 
(eg, RNA and protein based) are also actively under study both for use independently and as 
adjuncts to the currently available tests. This mini review provides current, state of the art 
knowledge about noninvasive stool based screening. It includes a more detailed examination of 
those tests currently in use (ie, FIT and sDNA) but also provides an overview of stool testing 
options under development (ie, protein and RNA). 
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Stool Testing for Colorectal Cancer Screening 
Colorectal cancer (CRC) screening is available across the United States, Europe, and 
Asia. Unlike screening tests for breast and prostate cancer, there is strong evidence that CRC 
screening reduces disease-specific morbidity and mortality.1 For fecal occult blood testing2 and 
flexible sigmoidoscopy,3 and 4 several large randomized trials show a mortality benefit, whereas 
observational studies show a mortality benefit for colonoscopy5 and 6 relative to usual care. 
Although CRC screening is widely available, the specifics of the programs vary across 
countries. Programmatic screening with fecal occult blood, flexible sigmoidoscopy, and 
colonoscopy has been successfully used in Canada, Europe and Asia. In the United States, 
screening is largely opportunistic7 and guidelines endorse a panel of options.8 Evidence suggests 
that colonoscopy is currently the dominant approach9 and so the role of the gastrointestinal 
specialist has largely been centered on providing high quality endoscopy. However, market 
forces may impact this practice. Gastrointestinal specialists likely will be increasingly relied 
upon to develop CRC screening programs for the populations they serve.10 In this capacity, 
knowledge about noninvasive stool based options will become increasingly important. 
This mini-review provides current, state of the art knowledge about noninvasive stool 
based screening. The key advantages of noninvasive screening approaches are reviewed and the 
current state of evidence supporting such use summarized (Table 1). The review more closely 
details clinically available tests (ie, fecal immunochemical testing [FIT] and stool DNA [sDNA]) 
but also provides an overview of stool testing options under development (ie, protein and RNA) 
Desirable Features of a Screening Test 
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Several features are desirable for a screening test or, when repeated testing over time is 
instituted, a screening program. Since screening involves testing asymptomatic people who are 
mostly healthy, a screening test must be low risk both directly (ie, the test itself must not cause 
harm) and indirectly (ie, downstream risks resulting from the need for subsequent testing). 
Related to this latter concept is the false-positive rate, which is a function of specificity. A test 
with high specificity and low false positive rate reduces risks of harm from both unnecessary 
testing and overdiagnosis.11 It also helps reduce the cost of screening, another desirable feature, 
particularly from a population-based perspective. Of course, the test should be able to detect the 
target lesion, making sensitivity of the test or program very important. For CRC screening, a 
noninvasive test as considered in this review should be able to detect curable-stage CRC, and if 
not on the first round of testing, then with the next round of testing, before a curable CRC 
becomes incurable. The degree to which a test should detect pre-cancerous lesions, most of 
which never progress to CRC, is debatable and beyond the scope of this review. Given the 
relatively long dwell time for neoplastic progression,12 a test with reasonable programmatic 
sensitivity may be adequate. Finally, a screening test should be widely available, affordable, and 
user-friendly, features required to optimize test uptake and adherence. 
From a practical perspective, a “good” noninvasive test affords several advantages for 
both patients and health systems. Patient advantages include an opportunity to better match the 
screening test to individual preferences and the factors they value.13 There is evidence that 
offering individuals a choice of screening options improves adherence with subsequent testing.14 
From a systems or societal perspective, availability of noninvasive testing may increase the reach 
of CRC screening programs to include at least some of the 35% of the US population who are 
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not current with CRC screening.9 To the extent that these noninvasive approaches are less costly 
than their structural counterparts, they can free resources for other worthwhile interventions. 
Quality of Evidence 
Evidence is lacking for which screening test and strategy are best and for the cumulative 
benefits and harms of screening. Optimal evidence would derive from a population-based 
randomized trial comparing all recommended screening strategies to either “no screening” or 
“usual care” with CRC mortality as the primary endpoint. Of course, logistical and ethical 
reasons preclude the feasibility of such a trial, resulting in the need to make clinical decisions 
using lower quality evidence. 
It is clear that noninvasive screening with stool testing works and has durable benefits. 
Long-term follow-up of persons randomized to guaiac-based fecal occult blood test (gFOBT) or 
usual care demonstrated a 32% reduction in CRC mortality after 30 years of follow-up.15 
However, gFOBT has limitations largely because of its reliance on detecting a more nonspecific 
marker for bleeding (ie, heme through a peroxidase reaction). Newer tests like FIT and sDNA 
have clear biological advantages over gFOBT16; however, the evidence for these tests is less 
mature.17 For FIT and a select few sDNA18, 19 and 20 panels, there are cross-sectional, 
population-based studies in which colonoscopy is the reference standard. These studies provide a 
reasonable estimate of one-time test characteristics, providing data for simulation modeling of 
the cumulative benefits, harms, and costs. Studies of stool-based micro-RNA (mi-RNA), protein 
and metabolic markers are nearly all case-control studies, which are considered to be preliminary 
or hypothesis-generating because of their tendency toward bias and need for subsequent testing 
using a more robust study design. 
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Fecal Immunochemical Testing 
FIT uses labeled antibody to detect the globin portion of human hemoglobin. 
Mechanistically, this translates to a number of significant advantages over gFOBT (Table 2). 
Approved FIT is marketed as either qualitative or quantitative and use slightly different 
analytical techniques. Qualitative tests use lateral flow immunochromatographic analysis and 
signal positive at a preset hemoglobin cutoff. Quantitative tests directly measure hemoglobin 
concentration using immunoturbidimetric methods. To date, quantitative FIT has been used 
qualitatively with the test simply reported as “positive” above a certain threshold based on 
manufacturer recommendation. However, opportunity exists to leverage the quantitative data 
contained in the measurement. 
Many studies have assessed the performance of one-time FIT using a colonoscopy gold 
standard to determine test characteristics for cancer and advanced adenoma in average risk 
screening populations. Interpretation of this literature is complicated because test performance 
can vary based upon the brand of the test, hemoglobin threshold defining a positive test, and 
number of tests applied in a single round of testing. A recently published meta-analysis 
summarized best available data and determined that overall sensitivity of one time FIT for cancer 
was 79% with a specificity of 94%.21 Among the subgroup of studies in which colonoscopy was 
the reference standard, cancer sensitivity was 71%. Not surprisingly, FIT sensitivity for 
advanced adenoma is significantly less and varies markedly depending upon the brand of test and 
cut-offs used. In one study comparing 6 qualitative FIT results, the 2 best performing tests had a 
sensitivity of approximately 25% for advanced adenoma.22 
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There is growing evidence regarding performance of FIT after multiple rounds of 
testing.23, 24 and 25 In an Italian population based screening program (n = 2959), nearly 50% 
attended all 4 rounds of screening. 23 Although the cancer detection rate declined over the 4 
screening rounds (suggesting identification and removal of cancers over time), advanced 
adenoma detection remained quite consistent (approximately 33%). The results suggest that 
long-term adherence with FIT may subsequently translate into reduced cancer incidence through 
continued removal of advanced neoplasia over time. 
Although our understanding of FIT’s ability to detect neoplasia has grown, significant 
questions remain. For example, deciding whether to use qualitative or quantitative FIT as well as 
the frequency and cut offs to use to define a positive test are all areas of active investigation. In 
this brief review it is not possible to review the evidence surrounding each of these questions, but 
some general statements can be made. Although there is some evidence that test characteristics 
comparing qualitative and quantitative FIT are quite similar,21 concerns regarding quality 
control with qualitative tests have been raised.26 Also quantitative testing allows the opportunity 
to select a test with a hemoglobin cut off that best matches available endoscopic resources. Given 
these types of advantages, there is growing enthusiasm for the adoption of quantitative FIT over 
qualitative tests.27 
Quantitative FIT affords the opportunity to set the test to a desired hemoglobin threshold 
that maximizes detection and minimizes false positive rates. That being said, determining the 
optimal hemoglobin threshold for screening is challenging. Factors such as age and gender 
influence fecal hemoglobin concentration,28 partly because the prevalence of neoplasia varies by 
these two factors. Also, studies of FIT have lacked consistency when reporting hemoglobin 
quantification with a given device. Efforts to standardize reporting29 are underway and should 
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improve the quality of the literature determining optimal threshold for a positive test. In the 
interim two recent systematic reviews suggest that lower thresholds (<20 μg of hemoglobin/g of 
stool) effectively balance test characteristics and improve cost effectiveness.21 and 30 Moving 
forward, it may well be possible to leverage knowledge of quantitative results to prioritize those 
most needing colonoscopy. A recent study identified a hemoglobin threshold of >177 μg 
hemoglobin/g of stool as an independent risk factor for advanced neoplasia after adjusting for 
factors such as sex and age (OR, 3.8; 95% confidence limit [CL], 3.07, 4.71).31 
Aside from research addressing the practical questions just discussed, other work to 
enhance understanding of FIT remains to be done. Large randomized trials directly assessing FIT 
versus colonoscopy as a primary tool for cancer screening are underway,32 and 33 but results 
will not be available for a decade or more. Although 1 recent study directly comparing 2 brands 
of FIT on important outcomes (eg, CRC mortality) has recently been reported,34 more 
comparative studies of other FIT brands and other noninvasive tests (like sDNA) are needed. The 
role of FIT as a screening tool in higher risk populations (eg, family history) or as an adjunct to 
surveillance have both recently been examined,35 and 36 but more work is needed to understand 
the utility of FIT outside of average risk screening. Finally, studies aimed at understanding how 
to optimize FIT-based screening to maximize adherence both with completion of the initial 
screen and follow-up colonoscopy when FIT positive are needed. 
Stool-Based DNA Testing 
The biological rationale is strong for measuring mutated DNA in stool. Colonocytes are 
continuously shed into the lumen; neoplastic cells exfoliate at a higher rate and include DNA that 
remains intact (ie, long) and is easier to detect than is fragmented DNA,37 Point mutations in 
oncogenes or tumor suppressor genes are specific for cancer and precancerous lesions. 
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Many of the published reports consists of comparing either single DNA mutations or 
panels of mutations in cases with CRC and controls without CRC, and may or may not include a 
group of subjects with precancerous (adenomatous) polyps. This literature is heterogeneous with 
respect to sample size, case selection and stage, DNA markers, control groups, and study 
findings. In contrast to evaluation of other nonhemoglobin stool-based markers, sDNA has been 
evaluated in population-based studies in the screening setting with colonoscopy as the reference 
standard. One of two such studies evaluated an early panel of DNA markers, specifically 21 
point mutations involving KRAS and APC, BAT-26 (a marker of microsatellite instability), and 
a DNA integrity assay in 2507 asymptomatic persons 50 years of age or older (and compared the 
panel to Hemoccult II (Beckman Coulter, Inc, Brea, CA), a gFOBT).20 Cancer sensitivity was 
52% for the panel vs 13% for Hemoccult II, and advanced adenoma sensitivity was 15.5% (vs 
10.6% for Hemoccult II). In a parallel study of 4,482 average-risk adults, cancer sensitivity and 
specificity using the same marker panel were 25% and 96%, respectively.18 A second DNA 
panel that included APC, KRAS, and methylated vimentin, was tested during the latter half of 
this study and showed higher sensitivity (58%) but lower specificity (84%).18 Sensitivity for 
adenomas 1 cm or larger was 46%. The results from these two studies were disappointing, 
particularly because of the high cost of the test, which precluded repeating it at short intervals. 
Although this first generation sDNA test was recommended by some guideline organizations,38 
and 39 its use in clinical practice was undetectable. 
Subsequent studies included better markers, buffers for stool stabilization, and more 
analytically sensitive measurement. Ahlquist and colleagues40 used quantitative allele-specific 
real-time target and signal amplification to test 4 methylated genes (NDRG4, BMP3, vimentin, 
and TFPI2), KRAS, and hemoglobin by immunoassay on archived specimens from 252 subjects 
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with CRC, 293 colonoscopy-negative controls, and 133 subjects with adenomas 1 cm or larger. 
At respective specificities for CRC and large adenomas of 90% and 89%, sensitivities were 85% 
for CRC and 54% for large adenomas, with no difference in sensitivity between proximal and 
distal CRCs or large adenomas. These encouraging findings led to the pivotal study for this 
marker panel, in which nearly 10,000 asymptomatic persons 50 to 84 years of age were tested 
with commercially available FIT and a multitarget sDNA panel, which consists of molecular 
assays for aberrantly methylated BMP3 and NDRG4 promoter regions, mutant KRAS and β-
actin (a reference gene for human DNA quantity) as well as an immunochemical assay for 
human hemoglobin, prior to undergoing screening colonoscopy. Quantitative measurements of 
each marker were incorporated into a validated logistic regression equation, with a value of 183 
or more indicative of a positive test. CRC sensitivity was 92.3% for the panel and 73.8% for FIT, 
with respective specificities of 86.6% and 94.9%. Sensitivity for advanced, precancerous polyps 
was 42.4% for the panel and 23.8 for FIT.19 The sDNA panel was superior to FIT for detection 
of lesions with high-grade dysplasia (69.2% vs 46.2%, respectively) and for sessile serrated 
polyps 1 cm or greater (42.4% vs 5.1%, respectively). The numbers of persons who need to be 
screened to detect one CRC were 154 for colonoscopy, 166 for the sDNA panel, and 208 with 
FIT. This stool-based, multitarget panel was approved with a 3-year testing interval by the Food 
and Drug Administration in August of 2014, and approved for reimbursement by the Centers of 
Medicare and Medicaid Services shortly afterwards at a cost of $492.72 (the list price is $599). 
The test must be ordered from a physician’s office through direct communication with the 
company providing the test (Cologuard, Exact Sciences Corporation, Madison, WI). 
Protein 
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Although gFOBT and FIT rely on detection of the protein hemoglobin as a marker of 
colorectal neoplasia, a number of other protein-based markers have been examined. These 
candidate biomarkers fall into two broad classes. Some tests rely on the detection of proteins 
released from products in the serum and might be expressed from inflamed and/or bleeding 
tissue. Other assays focus on detecting cancer-specific fecal proteins. 
Calprotectin, a calcium binding protein found largely in neutrophils, has been the most 
widely studied of the noncancer specific proteins. However, most of the studies are small case-
control studies that were not performed within the target population of interest (ie, average risk 
screening). One of the best evaluations of the marker was performed using stool samples 
obtained on individuals participating in the Norwegian Colorectal Cancer Prevention Screening 
trial (n = 2321) where the performance of calprotectin was compared with FIT. 41 Calprotectin 
detected fewer cancers than FIT, and had lower overall specificity. Calgranulin B, one of the 
components of calprotectin, has separately been studied; its test characteristics do not support its 
use for screening.42 
Of the cancer-related fecal proteins, tumor M2 pyruvate kinase (M2-PK) has received the 
most attention as a potential stool biomarker for cancer screening. A recently reported meta-
analysis summarized 10 observational studies (6 case-control and 4 cohort) of M2-PK and only 
included those studies where colonoscopy was performed in all study participants.43 The pooled 
CRC sensitivity and specificity were 79% and 81%, respectively. The authors specifically looked 
at 4 studies that compared M2-PK to FIT and found that the diagnostic odds ratio favored FIT 
(67.2 for FIT vs 9.5 for M2-PK, respectively). 
Although there is no single fecal protein biomarker superior to FIT, there may be a role 
for use of these tests either in combination with FIT or applied as a panel of tests. Leen and 
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colleagues included a M2-PK test kit along with a FIT as part of a FIT-based program.44 During 
that screening round 13 advanced adenomas were detected and 2 were specifically found because 
M2-PK was added (FIT detected 11 of 13 lesions). However, the positivity rate of the M2-PK 
was extremely high (27%) relative to FIT (6%); the lower specificity of M2-PK would markedly 
increase colonoscopy use for a relatively small gain in detection. 
Looking for a combination of fecal protein markers may eventually be possible. There 
have been improvements in technology to examine the metaproteomics of the gut through 
shotgun mass spectrometry of stool.45 Using this approach, Verberkmoes demonstrated that 
about 1/3 of proteins isolated in stool come from the human host and may theoretically be a 
biomarker target. Karl and colleagues46 examined 6 protein markers in 551 samples collected in 
a cohort that was enriched with patients with known cancer. Using Bayes logistic regression 
modeling, they identified a pair of markers (S100A12 and hemoglobin-haptoglobin) that 
demonstrated high sensitivity (88%) and specificity (95%) for cancer. Importantly, these results 
were not derived in a screening cohort, nor were they externally validated. Similarly, a study in 
20 cancer cases and an equal number of healthy controls examined the use of fecal protein 
biochips with simultaneous assessment of seven different protein markers and demonstrated 
sensitivity for cancer of 70% and a specificity of 40%.47 Although these 2 studies provide some 
proof of principle regarding combination panel testing, such strategies are far from clinical 
implementation. 
RNA Testing 
Two families of RNA have been studied as markers of colorectal neoplasia. Messenger 
RNA (mRNAs) were investigated initially, but found to be less stable in stool than DNA. During 
the last several years, investigation has turned to micro-RNAs (mi-RNAs), which are 18- to 25-
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nucleotide noncoding RNA molecules that regulate gene expression and translation, indirectly 
affecting cell differentiation, cell cycle progression, and apoptosis. More stable in stool and 
plasma than other nucleic acid molecules, mi-RNAs play either an oncogenic or tumor-
suppressor role in the multistep process of carcinogenesis, and are thought to be cell type- and 
disease-specific.48 In a clinical setting, mi-RNA may be quantified in stool by quantitative real-
time PCR (qPCR), which uses a reference gene49 or noncoding RNA transcript to quantify the 
relative amounts mi-RNA. 
Although a number of studies of single mi-RNAs and panels of mi-RNAs have been 
published, the field is still nascent. Several technical and analytical issues affecting measurement 
stability remain to be addressed. The more recent use of digital PCR likely represents a technical 
improvement that could accelerate scientific advancement. Similar to the sDNA literature, 
studies on mi-RNA are largely case-control studies of subjects with CRC compared with either 
“healthy” or colonoscopy result-negative subjects, with or without a third group with adenomas, 
and is quite heterogeneous in the specific single or panel of mi-RNA, study sample size, 
collection methods, and preparation, making comparisons challenging. Several of these 
pilot/hypothesis-generating studies show discrimination, but to a modest degree. Based on 
systematic review and independent validation, a tissue-based, differentially-expressed mi-RNA 
panel has been identified from analysis of CRC tissue and paired neighboring noncancerous 
colorectal tissue50; however, the panel has not yet been evaluated on stool specimens. Ahmed 
and colleagues51 have found differential expression of several mi-RNAs when comparing stool 
of cases with cancers to that of controls with no neoplasia; however, the results require 
independent validation. Of interest, only one differentially regulated mi-RNA (mi-106a) is 
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common to these two works, suggesting the need for independent validation, followed by large-
scale, population-based evaluation. 
Cost Effectiveness of Noninvasive Testing 
Several cost-effectiveness analyses show that CRC screening with either invasive or 
noninvasive tests is cost effective,52, 53, 54, 55 and 56 and annual FIT is often the first or 
second most cost-effective strategy in these models. In the cost-effectiveness analysis by 
Heitman and colleagues,52 annual FIT tests of medium and high test characteristics were the 
most effective and cost-effective strategies, whereas gFOBT and two (older) sDNA panels were 
least cost effective. More recently, Lansdorp-Vogelaar and colleagues57 used two 
microsimulation models to quantify the cost effectiveness of sDNA at a cost of $350 and used 
every 3 or 5 years among Medicare enrollees. Although sDNA at either interval provided fewer 
life-years and higher cost than other recommended CRC screening strategies, it would be cost 
effective at a cost of $40 to $60 at a 3-year interval, and at a cost of $350 if relative adherence to 
testing were at least 50% higher than other strategies. 
Conclusions 
Noninvasive testing for CRC has made great progress during the last decade and its 
trajectory, based on technical and analytical improvements and on active exploration of 
candidate markers, suggests continued rapid advancement. Both annual FIT and sDNA every 3 
years are viable noninvasive strategies for average-risk CRC screening and are both endorsed by 
current sub-speciality guidelines.39 and 58 Although a large randomized trial comparing annual 
FIT to sDNA every 3 years programmatically would be welcomed, such a study may be 
impractical as both technologies are evolving rapidly and the results of any long-term study 
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could be outdated before completion. Optimizing use of these tests in clinical practice requires a 
clearer understanding of risk for advanced colorectal neoplasia among “average-risk” persons, as 
well as a consideration of their test characteristics for CRC and advanced, precancerous lesions, 
testing interval, cost, and patient preference. If progress in noninvasive marker discovery 
continues at its current pace, we expect further improvements in marker discrimination, higher 
test throughput at lower cost, and more user-friendly testing, with a resulting expected decrease 
in the use of colonoscopy as a primary screening test among average-risk persons. High-quality 
noninvasive testing is the likely conduit to achieving higher adherence to CRC screening, with 
anticipated continued reductions in CRC incidence and mortality. 
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Table 1. Overview of Status and Supporting Evidence for Stool-Based Screening Tests 
Stool-Based 
Screening Test 
Status as a CRC 
Screening Test 
Examples Supporting Evidence 
FIT FDA approved Quantitative 
Oc Auto Micro 
Qualitative 
InSure 
ImmoCARE 
MonoHaem 
OC Light FIT CHEK 
 
Large Scale prospective 
studies in screening 
populations 
sDNA FDA approved Cologuard (key markers: 
methylation of BMP3 and NDRG4; 
KRAS; ß-actin; hemoglobin) 
 
Large scale cross- 
sectional studies in 
screening populations 
Protein In development Non-cancer-specific 
Calprotectin 
calgranulin B, 
lactoferrin 
Cancer-specific 
tumorM2-pyruvate kinase 
Clusterin 
 
Variable by marker; 
largely small cross 
sectional studies; often in 
populations with CRC or 
enriched with CRC 
RNA/miRNA In development Up-regulated (selected) 
miR-21 
miR-92a 
miR-106a 
miR-135b 
Down-regulated (selected) 
miR-9 
miR-29b 
miR-143 
Generally small scale 
proof of concept type 
studies (eg<comma> 
measuring markers in 
cancer tissue or stool) 
 
CRC, colorectal cancer; FDA, US Food and Drug Administration; FIT, fecal immunochemical testing; 
mi-RNA, micro-RNA. 
  
Table 2. Advantages of FIT Compared to Conventional Guaiac-based Fecal Occult Blood Test 
Biological Advantage Clinical Improvement 
Directly measures human 
hemoglobin 
•Highly sensitive for cancer even with single sample testing with some 
devices (improved compliance) 
•Maintains specificity even at higher levels of sensitivity (fewer false 
positive tests requiring definitive colon evaluation) 
•No need to adjust diet (improved compliance) 
 
Hemoglobin released from 
upper GI tract degraded in 
transit 
•No need to adjust drug intake like NSAIDs or anticoagulants 
(improved compliance) 
•Fewer false positives from the upper GI tract (ie, improved specificity) 
 
Hemoglobin measurement 
can be quantified 
•Definition of a positive test can be matched to colonoscopy resources 
•Opportunity to use quantitative value to stratify risk 
 
Hemoglobin measurement 
can be automated 
•Reduces the likelihood that results are impacted by quality control 
issues 
•Facilitates high throughput (eg, population based) screening efforts 
 
 
FOBT, fecal occult blood test; GI, gastrointestinal (tract); NSAID, nonsteroidal anti-inflammatory drug. 
